<DOC>
	<DOCNO>NCT00195000</DOCNO>
	<brief_summary>The purpose study find safe effective combination Mylotarg combination cytarabine treat patient Acute Myeloid Leukemia advance Myelodysplastic Syndrome age 60 year .</brief_summary>
	<brief_title>Mylotarg Ara-C Untreated Patients Above 60 Years With AML High-Risk MDS</brief_title>
	<detailed_description>To evaluate safety efficacy gemtuzumab ozogamicin combination cytarabine induce complete remission patient AML advance MDS age 60 year . Patients eligible treatment receive following : Mylotarg 6 mg/m2 day 1 2 hour intravenous infusion Cytarabine 100 mg/m2/day continuous intravenous infusion daily 7 day</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<criteria>Histologic diagnosis AML advance MDS No prior cytotoxic treatment AML . ( patient may treat prior biologic therapy ) Patients MDS AML evolve MDS , could receive prior lowdose cytotoxic therapy ( i.e . azacytidine lowdose araC ) . Uncontrolled severe cardiovascular disease pulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
</DOC>